Audet & Partners, LLP reports that consolidated Risperdal birth defect lawsuits now being heard in Philadelphia Court of Common Pleas (Risperdal Litigation, Case No. 100300296) are moving forward.  Issues related to the litigation against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, will be discussed in court on Tuesday, May 13, 2014 at 10:30 a.m. To learn more about pending Risperdal lawsuits, contact Audet & Partners, LLP by calling (800) 965-1461, or by completing and submitting our confidential inquiry form on... Read More

New research presented at the American Association for Geriatric Psychiatry (AAGP) 2014 Annual Meeting appears to substantiate the link between Johnson & Johnson’s drug Risperdal and gynecomastia, the development of breasts in men and young boys in a condition being referred to as Risperdal Gynecomastia. The research was presented by Dr. Mahyar Etminan, a prominent pharmaceopidemiologist and lead researcher at the University of British Columbia.  The team of researchers studied tens of thousands of patients to examine side effects of the... Read More